15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Pyxis Oncology Inc, 8 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $5.00 to $12.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $7.50 sits 93% above the current $3.88. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.26 next quarter toward $-1.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Strong Buy
Strong Buy00%
Buy8100%
Hold00%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Pyxis Oncology Inc.
As of Sep, 8 of 8 firms rate PYXS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PYXS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.26
Range $-0.38 – $-0.18 · 9 analysts · -10% YoY
Next period, 9 analysts expect Pyxis Oncology Inc to earn $-0.26 a share (range $-0.38 – $-0.18), versus $-0.29 a year earlier. Full-year consensus is $-1.22, growing to $-1.13 the year after.
REVENUE · NEXT QUARTER
$19.4K
Range $0 – $175.0K · 9 analysts · -100% YoY
Revenue is expected to reach $19.4K (range $0 – $175.0K), -99.8% year-over-year. Full-year consensus is $19.4K, rising to $2.8M next year.
Top analysts covering Pyxis Oncology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PYXS.
#1
Leonid Timashev
RBC Capital · Rank #33
Buy
$5.00+28.9% to target
Overall win rate
48%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #252
Buy
$7.00+80.4% to target
Overall win rate
38%
+ Follow
#3
SW
Stephen Willey
Stifel · Rank #345
Buy
$8.00+106.2% to target
Overall win rate
31%
+ Follow
#4
Robert Driscoll
Wedbush · Rank #375
Buy
$6.00+54.6% to target
Overall win rate
30%
+ Follow
#5
Derek Archila
Wells Fargo · Rank #390
Buy
$12.00+209.3% to target
Overall win rate
35%
+ Follow
PYXS stock forecast FAQ
What is PYXS's average 12-month price target?+
The 8 analysts with a live target average $7.50 for Pyxis Oncology Inc over the next 12 months, ranging from a $12.00 high to a $5.00 low.
Is PYXS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 8 analyst ratings, 8 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PYXS?+
The Street-high target is $12.00 (Wells Fargo), and the Street-low is $5.00 (RBC Capital). The average of all 8 active targets is $7.50.
How many Wall Street analysts cover PYXS?+
8 analysts have an active rating on Pyxis Oncology Inc, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering PYXS?+
Among analysts who currently cover PYXS, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #33). Their current call is Buy with a $5.00 target.
What is Pyxis Oncology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.26 per share (range $-0.38 – $-0.18) across 9 analysts. Full-year EPS is projected at $-1.22, rising to $-1.13 the following year.
How much revenue is Pyxis Oncology Inc expected to report next quarter?+
Consensus revenue is $19.4K (range $0 – $175.0K). Full-year revenue is projected at $19.4K, growing to $2.8M next year.
Have analysts been upgrading or downgrading PYXS lately?+
As of Sep, 8 of 8 firms rate PYXS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PYXS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
